Reports: Watson Pharma Close To Buying Actavis In A $7 Bln Deal

RELATED NEWS

Trade ACT now with

3/22/2012 1:13 AM ET

Generic drugmaker Watson Pharmaceuticals, Inc. Co. (WPI: Quote) is reportedly close to acquiring privately-held European peer Actavis for about $7 billion. The news sent Watson's shares soaring, which closed higher by nearly 9 percent.

The Swiss firm was taken private in 2007 and Icelandic business tycoon Bjorgolfur Thor Bjorgolfsson has a 78 percent stake in the company.

Parsippany, New Jersey-based Watson's offerings include generic version of cholesterol drug Lipitor and Concerta, intended for attention deficit hyperactivity disorder. The company last month reported a surge in profit for the fourth quarter mainly on strong sales of these two drugs. Actavis also has a business nearly as big as that of Watson and has a formidable presence in central and eastern Europe. It has around 830 products on the market and about 350 products under development and pending registration. The U.S. company may pay 5.0 billion euros to 5.5 billion euros for the Swiss firm.

Among its previous acquisitions, Watson purchased Andrx Corp in 2006 for $1.9 billion and bought Arrow Group for $1.75 billion in 2009. The company last year acquired Specifar Pharmaceuticals of Greece for $562 million.

WPI climbed $5.16 or 8.82 percent on Wednesday to close the session at $63.69 on a volume of 10.86 million shares.

To receive FREE breaking news email alerts for Actavis Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

<<Previous 59 Articles

Editors Pick

RBA Minutes: Inflation Forecast May Provide For Further Easing

Members of the Reserve Bank of Australia's monetary policy board felt that the central bank could still allow for additional monetary easing because inflation remains in check, minutes from the bank's June 4 meeting revealed on Tuesday. The easing might become necessary down the road, the bank said, since domestic growth has remained slightly below trend through the last four quarters. Global economic activity has been in line with forecasts, the minutes showed.

China May Leading Index Signals Weaker Economic Growth Ahead

A leading indicator of Chinese economic activity rose marginally in May and at a slower pace than a month earlier, suggesting more sluggish growth for the overall economy in the months ahead. The Conference Board said that its leading economic indicator rose 0.3 percent month-on-month in May, slower than a 1.5 percent increase in April. Only three of the six components contributed positively.

Stocks Close Mostly Higher Despite Afternoon Pullback - U.S. Commentary

While lingering worries about the outlook for the Federal Reserve's stimulus program generated some selling pressure in afternoon trading on Monday, stocks managed to end the day mostly higher after seeing an early rally on the heels of some upbeat economic data. The major averages finished the session well off their best levels of the day but still posted strong gains.